-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Benzinga·07/31/2026 17:54:33
语音播报
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $445 to $350.